10.30 | 7.40 – Liquid Lessons Learned From 2020 – Regulatory, Supply Chain, Payer & The Patients
Time: 10:30 am
day: Day Three
- Reflecting on recent FDA approvals– What are the key regulatory considerations for liquid biopsy
companion diagnostic tests?
- Liquid biopsy application is making signification contribution in cancer care seen by patients, but what challenges need to be overcome and knowledge gaps filled to support future liquid biopsy applications?
- What can we learn from recent supply chain disruptions resulting from the coronavirus pandemic to reduce delays in diagnostics reaching patients
- Tying together key considerations for liquid biopsy development and integration into therapeutic
programmes, and the importance of keeping regulatory, supply chain, payer & the patient priorities front of mind from the beginning